

Disclosure of total number of voting rights and number of shares in the capital as of March 31, 2025

Pursuant to article L-223-8 II of the French “code de Commerce” and 223-16 of the AMF’s General Regulations.

Total number of shares	18,859,216
Number of real voting rights* (excluding treasury shares**)	18,785,889
Theoretical number of voting rights* (including treasury shares**)	18,836,016

(*) Class E preference shares are non-voting

(**) pursuant to article 223-11 of the AMF’s General Regulations



About Median Technologies: Pioneering innovative software as a medical device and imaging services, Median Technologies harnesses cutting-edge AI to enhance the accuracy of early cancer diagnoses and treatments. Median's offerings include iCRO, which provides medical image analysis and management in oncology trials, and eyonis™, an AI/ML tech-based suite of software as a medical device (SaMD). Median empowers biopharmaceutical entities and clinicians to advance patient care and expedite the development of novel therapies. The French-based company, with a presence in the U.S.

and China, trades on the Euronext Growth market (ISIN: FR0011049824, ticker: ALMDT). Median is also eligible for the French SME equity savings plan scheme (PEA-PME). For more information, visit www.mediantechologies.com.

Contacts

Median Technologies

Emmanuelle Leygues

VP, Corporate Marketing & Financial Communications

+33 6 10 93 58 88

emmanuelle.leygues@mediantechnologies.com

Investors - ACTIFIN

Ghislaine Gasparetto

+33 6 21 10 49 24

ghislaine.gasparetto@seitosei-actifin.com

Press – Ulysse Communication

Bruno Arabian

+33 6 87 88 47 26

barabian@ulyse-communication.com

Nicolas Entz

+33 6 33 67 31 54

nentz@ulyse-communication.com